Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Computacenter adjusted operating profits seen slightly ahead of FY24

(Sharecast News) - IT support and services firm Computacenter said on Monday that it continues to expect FY25 adjusted operating profits to be ahead of FY24 after delivering "strong revenue growth" in H1. Computacenter stated that its increased revenues were primarily driven by growth in its high-volume technology sourcing business, resulting in "good growth" in gross profits.

The FTSE 250-listed group said this reflected "an excellent performance" in North America and further growth in the UK. However, Computacenter did acknowledge that it had experienced softer trading in Germany and France during the Q2, principally due to temporary lower levels of public sector activity following political changes.

As a result, Computacenter now expects H125 adjusted operating profits to be "slightly ahead" H124's £81.1m outcome, including a roughly £2.0m hit from adverse currency translation.

Looking ahead, Computacenter said it was "encouraged" by its committed product order backlog at the half, which "remains healthy" across all geographies, positioning the group for H2.

"While the broader geopolitical and macro uncertainty is expected to persist, we anticipate some recovery in public sector activity in Germany in the second half while France is expected to remain challenging," said Computacenter. "Overall, we continue to expect FY adjusted operating profit in FY25 to be ahead of the prior year, including an adverse circa £4.0m currency translation impact, with adjusted profit before tax expected to be at a similar level to the prior year."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.